Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Operations (2017 - 2025)

Puma Biotechnology's Cash from Operations history spans 9 years, with the latest figure at 14400000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 7.73% year-over-year to 14400000.0; the TTM value through Dec 2025 reached 41800000.0, up 7.41%, while the annual FY2025 figure was 41800000.0, 7.41% up from the prior year.
  • Cash from Operations reached 14400000.0 in Q4 2025 per PBYI's latest filing, up from 9706000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 17259000.0 in Q3 2022 to a low of 26895000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 5627500.0, with a median of 10080500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: crashed 18648.65% in 2022, then surged 1272.35% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 5435000.0 in 2021, then surged by 241.36% to 7683000.0 in 2022, then skyrocketed by 36.08% to 10455000.0 in 2023, then soared by 49.28% to 15607000.0 in 2024, then dropped by 7.73% to 14400000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Cash from Operations are 14400000.0 (Q4 2025), 9706000.0 (Q3 2025), and 14094000.0 (Q2 2025).